Molnar O, Straciuc O, Mihutiu S, Lazar L
Curr Oncol. 2024; 31(5):2508-2526.
PMID: 38785469
PMC: 11119194.
DOI: 10.3390/curroncol31050188.
Wang X, Li S, Lin X, Lu Y, Mao C, Ye Z
Front Oncol. 2022; 12:958219.
PMID: 36324571
PMC: 9620719.
DOI: 10.3389/fonc.2022.958219.
Yang W, Qiang J, Tian H, Chen B, Wang A, Zhao J
Eur Radiol. 2017; 28(1):437-445.
PMID: 28779395
DOI: 10.1007/s00330-017-4989-3.
Stark M, Mynbaev O, Vassilevski Y, Rozenberg P
AJP Rep. 2017; 6(3):e352-e354.
PMID: 28078171
PMC: 5045307.
DOI: 10.1055/s-0036-1593444.
Zheng W, Xiong Y, Han J, Guo Z, Li Y, Li A
Br J Radiol. 2016; 89(1065):20150887.
PMID: 27340932
PMC: 5124911.
DOI: 10.1259/bjr.20150887.
Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide.
Liang P, Chang H, Hsu C, Chen L, Shih T, Liu T
Hepatol Int. 2015; 9(2):258-68.
PMID: 25788178
DOI: 10.1007/s12072-014-9557-1.
Validation of optimal DCE-MRI perfusion threshold to classify at-risk tumor imaging voxels in heterogeneous cervical cancer for outcome prediction.
Huang Z, Yuh K, Lo S, Grecula J, Sammet S, Sammet C
Magn Reson Imaging. 2014; 32(10):1198-205.
PMID: 25179141
PMC: 4348016.
DOI: 10.1016/j.mri.2014.08.039.
Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation.
Barnes S, Whisenant J, Loveless M, Yankeelov T
Pharmaceutics. 2012; 4(3):442-78.
PMID: 23105959
PMC: 3480221.
DOI: 10.3390/pharmaceutics4030442.
Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: cervical cancer as a model.
Mayr N, Huang Z, Wang J, Lo S, Fan J, Grecula J
Int J Radiat Oncol Biol Phys. 2012; 83(3):972-9.
PMID: 22208967
PMC: 4373343.
DOI: 10.1016/j.ijrobp.2011.08.011.
Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.
Mayr N, Yuh W, Jajoura D, Wang J, Lo S, Montebello J
Cancer. 2010; 116(4):903-12.
PMID: 20052727
PMC: 4362726.
DOI: 10.1002/cncr.24822.
Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer.
Yuh W, Mayr N, Jarjoura D, Wu D, Grecula J, Lo S
Invest Radiol. 2009; 44(6):343-50.
PMID: 19661844
PMC: 2782687.
DOI: 10.1097/RLI.0b013e3181a64ce9.
Optimization of perfusion CT protocol for imaging of extracranial head and neck tumors.
Bisdas S, Foo C, Thng C, Vogl T, Koh T
J Digit Imaging. 2008; 22(5):437-48.
PMID: 18454289
PMC: 3043720.
DOI: 10.1007/s10278-008-9122-3.
Dynamic contrast-enhanced MR imaging.
Padhani A
Cancer Imaging. 2008; 1:52-63.
PMID: 18194888
PMC: 4554704.
DOI: 10.1102/1470-7330/00/010052+12.
Delineation and segmentation of cerebral tumors by mapping blood-brain barrier disruption with dynamic contrast-enhanced CT and tracer kinetics modeling-a feasibility study.
Bisdas S, Yang X, Lim C, Vogl T, Koh T
Eur Radiol. 2007; 18(1):143-51.
PMID: 17701183
DOI: 10.1007/s00330-007-0726-7.
An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus.
Pereira A, Huddleston D, Brickman A, Sosunov A, Hen R, McKhann G
Proc Natl Acad Sci U S A. 2007; 104(13):5638-43.
PMID: 17374720
PMC: 1838482.
DOI: 10.1073/pnas.0611721104.
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.
Morgan B, Utting J, Higginson A, Thomas A, Steward W, Horsfield M
Br J Cancer. 2006; 94(10):1420-7.
PMID: 16670720
PMC: 2361281.
DOI: 10.1038/sj.bjc.6603140.
Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography.
Oshida K, Nagashima T, Ueda T, Yagata H, Tanabe N, Nakano S
Eur Radiol. 2005; 15(7):1353-60.
PMID: 15789211
DOI: 10.1007/s00330-005-2661-9.
Single-level dynamic spiral CT of hepatocellular carcinoma: correlation between imaging features and density of tumor microvessels.
Chen W, Min P, Song B, Xiao B, Liu Y, Ge Y
World J Gastroenterol. 2003; 10(1):67-72.
PMID: 14695771
PMC: 4717081.
DOI: 10.3748/wjg.v10.i1.67.
Assessment of metastatic cervical adenopathy using dynamic contrast-enhanced MR imaging.
Fischbein N, Noworolski S, Henry R, Kaplan M, Dillon W, Nelson S
AJNR Am J Neuroradiol. 2003; 24(3):301-11.
PMID: 12637272
PMC: 7973604.
Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade.
Jackson A, Kassner A, Annesley-Williams D, Reid H
AJNR Am J Neuroradiol. 2002; 23(1):7-14.
PMID: 11827869
PMC: 7975509.